Progress of researches on schistosomiasis-associated pulmonary arterial hypertension
10.16250/j.32.1374.2022060
- VernacularTitle:血吸虫病相关性肺动脉高压研究进展
- Author:
Yong-hui ZHU
1
,
2
,
3
,
4
;
Yu CAI
1
,
2
,
3
,
4
;
Yuan-dong JIANG
1
,
2
,
3
,
4
;
Wei-cheng DENG
1
,
2
,
3
,
4
Author Information
1. National Key Clinical Specialty of Schistosomiasis
2. Xiangyue Hospital Affiliated to Hunan Institute of Schistosomiasis Control
3. Hunan Institute of Schistosomiasis Control
4. WHO Collaborating Centre for Research and Control on Schistosomiasis in Lake Regions, Yueyang, Hunan 414000, China
- Publication Type:Journal Article
- Keywords:
Schistosomiasis;
Pulmonary arterial hypertension;
Pathogenesis;
Vascular remodeling;
Diagnosis;
Treatment
- From:
Chinese Journal of Schistosomiasis Control
2022;34(4):432-437
- CountryChina
- Language:Chinese
-
Abstract:
Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is categorized as WHO Group I PAH because its clinical manifestations, laboratory and hemodynamic features share with PAH of other etiologies, such as idiopathic, heritable, HIV and autoimmune disorders. Sch-PAH is usually a life-threatening complication of hepatosplenic schistosomiasis characterized by changes in the vascular wall, remodeling and vasoconstriction with lesions primarily located in the precapillary segments of the pulmonary vasculature, which may result in a marked and sustained increase in pulmonary vascular resistance, right ventricular failure and ultimately death. Although egg deposition into lung and subsequent inflammatory cascades are key factors in the pathogenesis of Sch-PAH, the exact pathogenesis, course of disease and treatment of Sch-PAH remain largely uncertain. This review mainly discusses the pathophysiological and immunological mechanisms of Sch-PAH, so as to provide insights into the clinical diagnosis and treatment of Sch-PAH.
